Recently, a phase I trial, investigating two NLRP3 inhibitors, NT-0796 and NT-0249, was successfully completed and this could be an opportunity to see similar therapeutic effects of these inhibitors in PD patients. Here, NLRP3 is linked to Parkinson disease.